Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1 study found for:    9430587 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Completed AZD2171 to Treat Children and Adolescents With Solid Tumors or Acute Myelogenous Leukemia
Conditions: Refractory or Recurrent Solid Tumors;   Acute Myelogenous Leukemia
Intervention: Drug: Cediranib, AZD2171, RECENTIN

Indicates status has not been verified in more than two years